Abstract:
The headquarters of Sandoz in Basle have been carrying out a primary research program on a new drug for the treatment of rheumatic diseases, and are intending to carry out a market research program in the USA, Germany and the UK to explore the potential market for this new drug. In the UK, Sandoz themselves have carried out group discussions which have produced information on basic medical attitudes to this disease area and its drug therapy.